Apoptin enhances the oncolytic activity of vaccinia virus in vitro

Molecular Biology

Volumn 47, Issue 5, 2013, Pages 733-742

  Kochneva, G V ^a,b   Babkina, I N ^b,c   Lupan, T A ^b   Grazhdantseva, A A ^a,b   Yudin, P V ^a,b   Sivolobova, G F ^a,b   Shvalov, A N ^b   Popov, E G ^a,b   Babkin, I V ^c   Netesov, S V ^a,b   Chumakov, P M ^a,d  

^a NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^b STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^c INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

apoptin; oncolytic activity; puromycin; recombinant vaccinia virus; transient dominant selection; virus growth factor

Indexed keywords

CHICKEN ANEMIA VIRUS; GYROVIRUS; VACCINIA VIRUS; VACCINIA VIRUS (STRAIN L-IPV);

EID: 84885573738     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893313050075     Document Type: Article

References (29)

1. Kochneva G. V., Sivolobova G. F., Yudina K. V., Babkin I. V., Chumakov P. M., Netesov S. V. 2012. Oncolytic poxviruses. Mol. Genet. Microbiol. Virol. 27(1), 7-15.
2. Marennikova S. S., Shchelkunov S. N. 1998. Patogennye dlya cheloveka ortopoksvirusy (Orthopoxviruses Pathogenic for Humans), Moscow: KMK.
3. Netesov S. V., Kochneva G. V., Loktev V. B., Svyatchenko V. A., Sergeev A. N., Ternovoi V. A., Tikunova N. V., Shishkina L. N., Chumakov P. M. 2011. Oncolytic viruses: Achievements and problems. Epidemiol. Sanitariya. 13(157), 10-17.
4. Chalikonda S., Kivlen M., O'Malley M., Dong X., McCart J., Gorry M., Yin X., Zeh H., Guo Z., Bartlett D. 2008. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 15, 5-25.
5. Breitbach C., Burke J., Jonker D., Stephenson J., Haas A., Chow L., Nieva J., Hwang T., Moon A., Patt R., Pelusio A., LeBoeuf F., Burns J., Evgin L., De Silva N., Cvancic S., Robertson T., Je J., Lee Y., Parato K., Diallo J., Fenster A., Daneshmand M., Bell J., Kirn D. 2011. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 477, 99-102.
6. Los M., Panigrahi S., Rashedi I., Mandal S., Stetefeld J., Essmann F. and Schulze-Osthoff K. 2009. Apoptin, a tumor-selective killer. Biochim. Biophys. Acta. 1793, 1335-1342.
7. Rohn J. L., Zhang Y. H., Aalbers R. I., Otto N., Den Hertog J., Henriquez N. V., van De Velde C. J., Kuppen P. J., Mumberg D., Donner P., Noteborn M. H. 2002. A tumor-specific kinase activity regulates the viral death protein apoptin. J. Biol. Chem. 277, 50820-50827.
8. Noteborn M. H. M. 2004. Chicken anemia virus induced apoptosis: Underlying molecular mechanisms. Vet. Microbiol. 98, 89-94.
9. Maddika S., Mendoza F. J., Hauff K., Zamzow C. R., Paranjothy T., Los M. 2006. Cancer-selective therapy of the future: Apoptin and its mechanism of action. Cancer Biol. Ther. 5, 10-19.
10. Maddika S., Panigrahi S., Wiechec E., Wesselborg S., Fischer U., Schulze-Osthoff K., Los M. 2009. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol. Cell. Biol. 29, 1235-1248.
11. Zhou S., Zhang M., Zhang J., Shen H., Tangsakar E., Wang J. 2012. Mechanisms of apoptin-induced cell death. Med. Oncol. 29, 2985-2991.
12. Noteborn M. H., Pietersen A. 2007. US Patent 7. 253. 150.
13. Zhang K., Qian J., Wang S., Yang Y. 2012. Targeting gene-viro-therapy with AFP driving apoptin gene shows potent antitumor effect in hepatocarcinoma. J. Biomed. Sci. 19, 20-32.
14. Rojas J., Thorne S. 2012. Theranostic potential of oncolytic vaccinia virus. Theranostics. 2(4), 363-373.
15. Wu Y., Zhang X., Wang X., Wang L., Hu S., Liu X., Meng S. 2012. Apoptin enhances the oncolytic properties of newcastle disease virus. Intervirology. 55, 276-286.
16. Li X., Jin N., Mi Z., Lian H., Sun L., Zheng H. 2006. Antitumor effects of a recombinant fowlpox virus expressing apoptin in vivo and in vitro. Int. J. Cancer. 119, 2948-2957.
17. Serpinsky O. I., Kochneva G. V., Urmanov I. Kh., Sivolobova G. F., Ryabchikova E. I. 1996. Construction of recombinant orthopoxvirus variants by inserting alien genes into the intergenic regioon of the viral genome. Mol. Biol. (Moscow). 30, 1064-1073.
18. Merchlinsky M., Eckert D., Smith E., Zauderer M. 1997. Construction and characterization of vaccinia direct ligation vectors. Virology. 238, 444-451.
19. Kim M., Yang H., Kim S., Reche P., Tirabassi R., Hussey R., Chishti Y., Rheinwald J., Morehead T., Zech T., Damon I., Welsh R., Reinherz E. 2004. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279(24), 25838-25848.
20. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. 1991. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83(11), 757-766.
21. Fenner F., Wittek R., Dumbell K. 1989. The Orthopoxviruses. NY: Academic Press.
22. Buller R., Chakrabarti S., Cooper J., Twardzik D., Moss B. 1988. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 62, 866-874.
23. Tzahar E., Moyer J. D., Waterman H., Barbacci E. G., Bao J., Levkowitz G., Shelly M., Strano S., Pinkas-Kramarski R., Pierce J. H., Andrews G. C., Yarden Y. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17(20), 5948-5963.
24. Falkner F. G., Moss B. 1990. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64, 3108-3111.
25. Kolosova I. V., Seregin S. V., Kochneva G. V., Ryabchikova E. I., Bessmel'tseva E. V., Babkina I. N., Solenova T. E., Babkin I. V., Shchelkunov S. N. 2003. Orthopoxvirus genes for kelch-like proteins: 2. Construction of cowpox virus variants with targeted gene deletions. Mol. Biol. (Moscow). 37, 495-502.
26. Kochneva G. V., Kolosova I. V., Lupan T. A., Sivolobova G. F., Yudin P. V., Grazhdantseva A. A., Ryabchikova E. I., Kandrina N. Yu., Shchelkunov S. N. 2009. Orthopoxvirus genes for kelch-like proteins: 3. Construction of mousepox (Ectromelia) virus variants with targeted gene deletions. Mol. Biol. (Moscow). 43, 567-572.
27. Noteborn M., Todd D., Verschueren A., de Gauw H., Curran W., Veldkamp S., Douglas A., McNulty M., van der EB A., Koch G. 1994. A single chicken anemia virus protein induces apoptosis. J. Virol. 68(1), 346-351.
28. Thorne S., Hwang T., O'Gorman W., Bartlett D., Sei S., Kanji F., Brown C., Werier J., Cho J., Lee D., Wang Y., Bell J., Kirn D. 2007. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350-3358.
29. Flinterman M., Farzaneh F., Habib N., Malik F., Gaken J., Tavassoli M. 2009. Delivery of therapeutic proteins as secretable TAT fusion products. Mol. Ther. 17, 334-342.